nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—prostate cancer	0.811	1	CbGaD
Tyloxapol—LPL—prostate gland—prostate cancer	0.0111	0.224	CbGeAlD
Tyloxapol—LPL—seminal vesicle—prostate cancer	0.00935	0.189	CbGeAlD
Tyloxapol—LPL—renal system—prostate cancer	0.00753	0.152	CbGeAlD
Tyloxapol—LPL—urethra—prostate cancer	0.0074	0.15	CbGeAlD
Tyloxapol—LPL—bone marrow—prostate cancer	0.0057	0.115	CbGeAlD
Tyloxapol—LPL—testis—prostate cancer	0.00487	0.0985	CbGeAlD
Tyloxapol—LPL—lymph node—prostate cancer	0.00353	0.0714	CbGeAlD
Tyloxapol—LPL—Metabolism—GSTA3—prostate cancer	0.000132	0.00095	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—TCN2—prostate cancer	0.000132	0.00095	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—JUP—prostate cancer	0.00013	0.000934	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—WNT4—prostate cancer	0.00013	0.000934	CbGpPWpGaD
Tyloxapol—LPL—Disease—LRP2—prostate cancer	0.000129	0.000924	CbGpPWpGaD
Tyloxapol—LPL—Disease—P4HB—prostate cancer	0.000126	0.000907	CbGpPWpGaD
Tyloxapol—LPL—Disease—EIF2AK2—prostate cancer	0.000126	0.000907	CbGpPWpGaD
Tyloxapol—LPL—Disease—RPL10—prostate cancer	0.000126	0.000907	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HSD3B1—prostate cancer	0.000126	0.000906	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SLC22A3—prostate cancer	0.000126	0.000906	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—IL6—prostate cancer	0.000125	0.000896	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—RALBP1—prostate cancer	0.000124	0.000891	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MC2R—prostate cancer	0.000124	0.000891	CbGpPWpGaD
Tyloxapol—LPL—Disease—HIST1H2BG—prostate cancer	0.000124	0.00089	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—PPARA—prostate cancer	0.000121	0.000869	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—TBXAS1—prostate cancer	0.000121	0.000869	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTA4—prostate cancer	0.000121	0.000869	CbGpPWpGaD
Tyloxapol—LPL—Disease—HIST1H4H—prostate cancer	0.00012	0.000859	CbGpPWpGaD
Tyloxapol—LPL—Disease—NPPA—prostate cancer	0.00012	0.000859	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	0.000118	0.000849	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTA2—prostate cancer	0.000118	0.000846	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SULT1A1—prostate cancer	0.000117	0.000836	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ABCG5—prostate cancer	0.000117	0.000836	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—LEP—prostate cancer	0.000115	0.000825	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTA1—prostate cancer	0.000114	0.000817	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—KDR—prostate cancer	0.000113	0.000808	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTO1—prostate cancer	0.000113	0.000807	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NAT2—prostate cancer	0.000113	0.000807	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HSD3B2—prostate cancer	0.000113	0.000807	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PENK—prostate cancer	0.000111	0.000794	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	0.000108	0.000776	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—LRP2—prostate cancer	0.000108	0.000774	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PLCB2—prostate cancer	0.000108	0.000774	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2C18—prostate cancer	0.000108	0.000774	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—P4HB—prostate cancer	0.000106	0.000759	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GHR—prostate cancer	0.000106	0.000758	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SLC22A1—prostate cancer	0.000103	0.000739	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFBR1—prostate cancer	0.000102	0.000731	CbGpPWpGaD
Tyloxapol—LPL—Disease—B2M—prostate cancer	0.000102	0.000731	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	0.000102	0.00073	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NRP1—prostate cancer	0.000101	0.000726	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SULT2A1—prostate cancer	0.0001	0.00072	CbGpPWpGaD
Tyloxapol—LPL—Disease—RPS19—prostate cancer	0.0001	0.000719	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKR1C3—prostate cancer	0.0001	0.000719	CbGpPWpGaD
Tyloxapol—LPL—Disease—PRKACB—prostate cancer	9.97e-05	0.000715	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—GSK3B—prostate cancer	9.96e-05	0.000714	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—MED12—prostate cancer	9.87e-05	0.000708	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—INS—prostate cancer	9.82e-05	0.000705	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GNG5—prostate cancer	9.79e-05	0.000702	CbGpPWpGaD
Tyloxapol—LPL—Disease—PPP3CA—prostate cancer	9.72e-05	0.000697	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CREBBP—prostate cancer	9.62e-05	0.00069	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NCOA3—prostate cancer	9.43e-05	0.000677	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VIP—prostate cancer	9.41e-05	0.000675	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNRH1—prostate cancer	9.41e-05	0.000675	CbGpPWpGaD
Tyloxapol—LPL—Disease—PRKCZ—prostate cancer	9.4e-05	0.000674	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	9.27e-05	0.000665	CbGpPWpGaD
Tyloxapol—LPL—Disease—CALR—prostate cancer	9.23e-05	0.000662	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP2—prostate cancer	9.2e-05	0.00066	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MAP2K1—prostate cancer	9.18e-05	0.000659	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LPAR1—prostate cancer	9.11e-05	0.000654	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GRP—prostate cancer	9.11e-05	0.000654	CbGpPWpGaD
Tyloxapol—LPL—Disease—PARP1—prostate cancer	9.08e-05	0.000651	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGFR4—prostate cancer	9.08e-05	0.000651	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PLCB2—prostate cancer	9.02e-05	0.000647	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LRP2—prostate cancer	9.02e-05	0.000647	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—HPGDS—prostate cancer	9e-05	0.000646	CbGpPWpGaD
Tyloxapol—LPL—Disease—CALCA—prostate cancer	8.97e-05	0.000643	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2C19—prostate cancer	8.94e-05	0.000641	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—P4HB—prostate cancer	8.85e-05	0.000635	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CX3CL1—prostate cancer	8.85e-05	0.000635	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—FGF2—prostate cancer	8.74e-05	0.000627	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTT1—prostate cancer	8.73e-05	0.000626	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ACHE—prostate cancer	8.73e-05	0.000626	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HIST1H2BG—prostate cancer	8.69e-05	0.000623	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2A6—prostate cancer	8.63e-05	0.000619	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PDE4D—prostate cancer	8.61e-05	0.000618	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GRB7—prostate cancer	8.61e-05	0.000618	CbGpPWpGaD
Tyloxapol—LPL—Disease—HSPA1A—prostate cancer	8.6e-05	0.000617	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.59e-05	0.000617	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKR1C3—prostate cancer	8.39e-05	0.000602	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HIST1H4H—prostate cancer	8.39e-05	0.000602	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—JAK2—prostate cancer	8.37e-05	0.000601	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PRKACB—prostate cancer	8.35e-05	0.000599	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP17A1—prostate cancer	8.26e-05	0.000593	CbGpPWpGaD
Tyloxapol—LPL—Disease—CASP9—prostate cancer	8.25e-05	0.000592	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNG5—prostate cancer	8.19e-05	0.000587	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.15e-05	0.000585	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—ERBB2—prostate cancer	8.06e-05	0.000578	CbGpPWpGaD
Tyloxapol—LPL—Disease—PRKCQ—prostate cancer	7.99e-05	0.000573	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NCOA2—prostate cancer	7.87e-05	0.000565	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGF10—prostate cancer	7.59e-05	0.000545	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SLC5A5—prostate cancer	7.51e-05	0.000539	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP2E1—prostate cancer	7.33e-05	0.000526	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NQO1—prostate cancer	7.25e-05	0.00052	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFBR2—prostate cancer	7.22e-05	0.000518	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—TH—prostate cancer	7.15e-05	0.000513	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFBR1—prostate cancer	7.13e-05	0.000512	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PTHLH—prostate cancer	7.13e-05	0.000512	CbGpPWpGaD
Tyloxapol—LPL—Disease—ITPR1—prostate cancer	7.11e-05	0.00051	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.1e-05	0.00051	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP3A4—prostate cancer	7.07e-05	0.000507	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CTNNB1—prostate cancer	7.05e-05	0.000506	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.04e-05	0.000505	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKR1C3—prostate cancer	7.02e-05	0.000503	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PRKACB—prostate cancer	6.98e-05	0.000501	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP1B1—prostate cancer	6.95e-05	0.000499	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP9—prostate cancer	6.91e-05	0.000496	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PPP3CA—prostate cancer	6.8e-05	0.000488	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—THBS1—prostate cancer	6.8e-05	0.000488	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GGT1—prostate cancer	6.73e-05	0.000483	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ANXA1—prostate cancer	6.71e-05	0.000481	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NCOA1—prostate cancer	6.63e-05	0.000476	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PRKCZ—prostate cancer	6.58e-05	0.000472	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—EP300—prostate cancer	6.55e-05	0.00047	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP19A1—prostate cancer	6.54e-05	0.000469	CbGpPWpGaD
Tyloxapol—LPL—Disease—PDGFRB—prostate cancer	6.46e-05	0.000463	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—SRC—prostate cancer	6.37e-05	0.000457	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGFR4—prostate cancer	6.36e-05	0.000456	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PARP1—prostate cancer	6.36e-05	0.000456	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—RXRA—prostate cancer	6.31e-05	0.000453	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CALCA—prostate cancer	6.28e-05	0.000451	CbGpPWpGaD
Tyloxapol—LPL—Disease—ERCC2—prostate cancer	6.24e-05	0.000448	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—VEGFA—prostate cancer	6.21e-05	0.000445	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—STAT3—prostate cancer	6.15e-05	0.000441	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.14e-05	0.00044	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL12—prostate cancer	6.13e-05	0.00044	CbGpPWpGaD
Tyloxapol—LPL—Disease—ERBB3—prostate cancer	6.1e-05	0.000438	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGFR2—prostate cancer	6.09e-05	0.000437	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—COMT—prostate cancer	6.08e-05	0.000436	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTP1—prostate cancer	6.05e-05	0.000434	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ITPR1—prostate cancer	5.95e-05	0.000427	CbGpPWpGaD
Tyloxapol—LPL—Disease—MTHFR—prostate cancer	5.87e-05	0.000421	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.85e-05	0.00042	CbGpPWpGaD
Tyloxapol—LPL—Disease—TERT—prostate cancer	5.85e-05	0.00042	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CASP9—prostate cancer	5.78e-05	0.000414	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TGFB1—prostate cancer	5.7e-05	0.000409	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—TYMS—prostate cancer	5.62e-05	0.000403	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PRKCQ—prostate cancer	5.6e-05	0.000402	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NGFR—prostate cancer	5.6e-05	0.000402	CbGpPWpGaD
Tyloxapol—LPL—Disease—HIF1A—prostate cancer	5.59e-05	0.000401	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—EGFR—prostate cancer	5.59e-05	0.000401	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GSTM1—prostate cancer	5.56e-05	0.000399	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MAP3K7—prostate cancer	5.53e-05	0.000397	CbGpPWpGaD
Tyloxapol—LPL—Disease—CAV1—prostate cancer	5.41e-05	0.000388	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGF10—prostate cancer	5.32e-05	0.000382	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—KRAS—prostate cancer	5.28e-05	0.000379	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CYP1A1—prostate cancer	5.27e-05	0.000378	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ADRB2—prostate cancer	5.26e-05	0.000378	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—ERCC2—prostate cancer	5.23e-05	0.000375	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VAV3—prostate cancer	5.13e-05	0.000368	CbGpPWpGaD
Tyloxapol—LPL—Disease—BAD—prostate cancer	5.09e-05	0.000365	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFBR2—prostate cancer	5.06e-05	0.000363	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ITPR1—prostate cancer	4.98e-05	0.000357	CbGpPWpGaD
Tyloxapol—LPL—Disease—APC—prostate cancer	4.93e-05	0.000354	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—MTHFR—prostate cancer	4.91e-05	0.000352	CbGpPWpGaD
Tyloxapol—LPL—Disease—IRS1—prostate cancer	4.87e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Disease—EGF—prostate cancer	4.87e-05	0.00035	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PPARA—prostate cancer	4.82e-05	0.000346	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IGF1R—prostate cancer	4.76e-05	0.000341	CbGpPWpGaD
Tyloxapol—LPL—Disease—GSK3B—prostate cancer	4.73e-05	0.000339	CbGpPWpGaD
Tyloxapol—LPL—Disease—INS—prostate cancer	4.67e-05	0.000335	CbGpPWpGaD
Tyloxapol—LPL—Disease—CREBBP—prostate cancer	4.57e-05	0.000328	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CAV1—prostate cancer	4.53e-05	0.000325	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PDGFRB—prostate cancer	4.52e-05	0.000324	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ITGB3—prostate cancer	4.41e-05	0.000316	CbGpPWpGaD
Tyloxapol—LPL—Disease—MAP2K1—prostate cancer	4.36e-05	0.000313	CbGpPWpGaD
Tyloxapol—LPL—Disease—PIK3CD—prostate cancer	4.33e-05	0.000311	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.33e-05	0.000311	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6—prostate cancer	4.29e-05	0.000308	CbGpPWpGaD
Tyloxapol—LPL—Disease—SERPINE1—prostate cancer	4.29e-05	0.000307	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ERBB3—prostate cancer	4.27e-05	0.000307	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGFR2—prostate cancer	4.27e-05	0.000306	CbGpPWpGaD
Tyloxapol—LPL—Disease—FGF2—prostate cancer	4.15e-05	0.000298	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CG—prostate cancer	4.13e-05	0.000296	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TERT—prostate cancer	4.1e-05	0.000294	CbGpPWpGaD
Tyloxapol—LPL—Disease—NOS3—prostate cancer	4.09e-05	0.000294	CbGpPWpGaD
Tyloxapol—LPL—Disease—JAK2—prostate cancer	3.98e-05	0.000285	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—AKT1—prostate cancer	3.96e-05	0.000284	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HIF1A—prostate cancer	3.92e-05	0.000281	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—INS—prostate cancer	3.91e-05	0.00028	CbGpPWpGaD
Tyloxapol—LPL—Disease—MDM2—prostate cancer	3.88e-05	0.000278	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—CREBBP—prostate cancer	3.83e-05	0.000275	CbGpPWpGaD
Tyloxapol—LPL—Disease—ERBB2—prostate cancer	3.83e-05	0.000275	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—LEP—prostate cancer	3.82e-05	0.000274	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CAV1—prostate cancer	3.79e-05	0.000272	CbGpPWpGaD
Tyloxapol—LPL—Disease—PIK3CB—prostate cancer	3.78e-05	0.000271	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KDR—prostate cancer	3.75e-05	0.000269	CbGpPWpGaD
Tyloxapol—LPL—Disease—PTGS2—prostate cancer	3.74e-05	0.000268	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ESR1—prostate cancer	3.65e-05	0.000262	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CD—prostate cancer	3.63e-05	0.00026	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—BAD—prostate cancer	3.56e-05	0.000256	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN1B—prostate cancer	3.54e-05	0.000254	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—APC—prostate cancer	3.45e-05	0.000248	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CG—prostate cancer	3.45e-05	0.000248	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—NOS3—prostate cancer	3.43e-05	0.000246	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EGF—prostate cancer	3.41e-05	0.000245	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IRS1—prostate cancer	3.41e-05	0.000245	CbGpPWpGaD
Tyloxapol—LPL—Disease—CTNNB1—prostate cancer	3.35e-05	0.00024	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GSK3B—prostate cancer	3.31e-05	0.000238	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN1A—prostate cancer	3.27e-05	0.000235	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—INS—prostate cancer	3.27e-05	0.000234	CbGpPWpGaD
Tyloxapol—LPL—Disease—PTEN—prostate cancer	3.26e-05	0.000234	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CREBBP—prostate cancer	3.2e-05	0.00023	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CB—prostate cancer	3.16e-05	0.000227	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IGF1—prostate cancer	3.16e-05	0.000227	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PTGS2—prostate cancer	3.13e-05	0.000225	CbGpPWpGaD
Tyloxapol—LPL—Disease—EP300—prostate cancer	3.11e-05	0.000223	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MAP2K1—prostate cancer	3.05e-05	0.000219	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CD—prostate cancer	3.03e-05	0.000218	CbGpPWpGaD
Tyloxapol—LPL—Disease—SRC—prostate cancer	3.03e-05	0.000217	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SERPINE1—prostate cancer	3e-05	0.000215	CbGpPWpGaD
Tyloxapol—LPL—Disease—STAT3—prostate cancer	2.92e-05	0.000209	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—FGF2—prostate cancer	2.91e-05	0.000208	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NOS3—prostate cancer	2.87e-05	0.000206	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—JAK2—prostate cancer	2.78e-05	0.0002	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PTEN—prostate cancer	2.73e-05	0.000196	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MDM2—prostate cancer	2.72e-05	0.000195	CbGpPWpGaD
Tyloxapol—LPL—Disease—MYC—prostate cancer	2.71e-05	0.000195	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFB1—prostate cancer	2.71e-05	0.000194	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ERBB2—prostate cancer	2.68e-05	0.000192	CbGpPWpGaD
Tyloxapol—LPL—Disease—EGFR—prostate cancer	2.65e-05	0.00019	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CB—prostate cancer	2.64e-05	0.00019	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—EP300—prostate cancer	2.61e-05	0.000187	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CXCL8—prostate cancer	2.54e-05	0.000182	CbGpPWpGaD
Tyloxapol—LPL—Disease—KRAS—prostate cancer	2.51e-05	0.00018	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN1B—prostate cancer	2.48e-05	0.000178	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CASP3—prostate cancer	2.43e-05	0.000175	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL2—prostate cancer	2.43e-05	0.000174	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCND1—prostate cancer	2.37e-05	0.00017	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CTNNB1—prostate cancer	2.34e-05	0.000168	CbGpPWpGaD
Tyloxapol—LPL—Disease—PIK3CA—prostate cancer	2.3e-05	0.000165	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MMP9—prostate cancer	2.3e-05	0.000165	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN1A—prostate cancer	2.29e-05	0.000164	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PTEN—prostate cancer	2.29e-05	0.000164	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EP300—prostate cancer	2.18e-05	0.000156	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SRC—prostate cancer	2.12e-05	0.000152	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—VEGFA—prostate cancer	2.06e-05	0.000148	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—STAT3—prostate cancer	2.04e-05	0.000147	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6—prostate cancer	2.04e-05	0.000146	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PIK3CA—prostate cancer	1.93e-05	0.000138	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MYC—prostate cancer	1.9e-05	0.000136	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFB1—prostate cancer	1.89e-05	0.000136	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKT1—prostate cancer	1.88e-05	0.000135	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EGFR—prostate cancer	1.86e-05	0.000133	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KRAS—prostate cancer	1.75e-05	0.000126	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—PIK3CA—prostate cancer	1.61e-05	0.000116	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKT1—prostate cancer	1.58e-05	0.000113	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TP53—prostate cancer	1.56e-05	0.000112	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6—prostate cancer	1.43e-05	0.000102	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKT1—prostate cancer	1.32e-05	9.45e-05	CbGpPWpGaD
